跳至主要内容
临床试验/NCT02427373
NCT02427373已完成不适用

A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil

DSM Nutritional Products, Inc.0 个研究点目标入组 66 人开始时间: 2014年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
66
主要终点
Comparison of total plasma DHA+EPA levels across 3 treatment groups

研究概览

简要总结

A multiple-dose, double-blind, randomized, four-week, three-treatment, parallel study in which 66 healthy adult subjects will receive 6 capsules/d, administered as a dose of 1.3 g/d eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) in fish oil ethyl ester (EE), or fish oil triglyceride (TG) or krill oil for a total of 4 weeks. The objective of the study is to compare the oral bioavailability of EPA+DHA in total plasma across the three formulations at the end of the 4 week study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •adult female who is neither pregnant nor breastfeeding, or
  • •a healthy, adult male
  • •with a body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and
  • •with a minimum weight of 50 kg (110 lbs).

排除标准

  • •history or presence of diabetes, high triglycerides (≥240 mg/dL), or high cholesterol (≥240 mg/dL);
  • •clinically significant abnormal finding on the physical exam, medical history, vital signs, or clinical laboratory results at screening;
  • •history or presence of allergic response to omega-3-fatty acids or sensitivity or allergy to fish or shellfish;
  • •history of coagulation disorder or current anticoagulation therapy;
  • •has used any nutritional supplements, omega-3 supplements, fish oil, chia, krill oil, flaxseed or foods supplemented with omega-3s within 3 months prior to the first dose of study medication;
  • •has used any prescription medication, except hormonal contraceptive or hormonal replacement therapy, within 14 days prior to the first dose of study medication.

研究组 & 干预措施

fish oil ethyl ester

Active Comparator

1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks

干预措施: fish oil ethyl ester (Dietary Supplement)

fish oil triglyceride

Active Comparator

1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks

干预措施: fish oil triglyceride (Dietary Supplement)

krill oil

Active Comparator

1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks

干预措施: krill oil (Dietary Supplement)

结局指标

主要结局

Comparison of total plasma DHA+EPA levels across 3 treatment groups

时间窗: 4 weeks

次要结局

  • pharmacokinetic parameter: AUC to 672hr(4 weeks)
  • Comparison of RBC DHA+EPA levels across 3 treatment groups(4 weeks)
  • pharmacokinetic parameter: Tmax(4 weeks)
  • pharmacokinetic parameter: Cmax(4 weeks)
  • pharmacokinetic parameter: AUC to 336hr(2 weeks)

研究者

发起方
DSM Nutritional Products, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验